PBYI News & Events

Reports Q1 revenue $44.8M vs $42M last year. "We are very pleased that the first quarter of 2026 marked another quarter of year-over-year demand increase resulting in our raising revenue guidance for 2026. According to our current forecasts, FY 2026 will mark our second consecutive year of NERLYNX demand increase year over year," said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. "We are also pleased with the interim data from ALISCA-Breast1 and ALISCA-Lung1, which appear to demonstrate an increased clinical effect of alisertib in biomarker subgroups where aurora kinase A appears to be playing a role. We look forward to continuing the development of alisertib in ALISCA-Breast1 and ALISCA-Lung1 while carefully managing our resources to achieve positive net income for this year."

Puma Biotechnology sees Q2 revenue $52M-$55M, one estimate $52M

Reports Q4 revenue $75.5M vs. $59.1M last year. "Our financial performance in the fourth quarter and full year 2025 demonstrates continued momentum, with net income marking our third consecutive year of profitability, a testament to our disciplined execution and careful fiscal stewardship," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "Our current guidance forecasts that we will continue to be profitable in 2026, which we believe is a result of this continued financial discipline. In parallel, we continue to advance alisertib clinically through ALISCA(TM)-Breast1 and ALISCA(TM)-Lung1, targeting patient populations in chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer and extensive-stage small cell lung cancer."